vs
Avantor, Inc.(AVTR)とSOMNIGROUP INTERNATIONAL INC.(SGI)の財務データ比較。上の社名をクリックして会社を切り替えられます
SOMNIGROUP INTERNATIONAL INC.の直近四半期売上が大きい($1.9B vs $1.7B、Avantor, Inc.の約1.1倍)。SOMNIGROUP INTERNATIONAL INC.の純利益率が高く(7.5% vs 3.1%、差は4.4%)。SOMNIGROUP INTERNATIONAL INC.の前年同期比売上増加率が高い(54.7% vs -1.4%)。Avantor, Inc.の直近四半期フリーキャッシュフローが多い($117.2M vs $41.1M)。過去8四半期でSOMNIGROUP INTERNATIONAL INC.の売上複合成長率が高い(25.3% vs -0.5%)
アバンター社は米国ペンシルベニア州ラドノーに本社を置くバイオテクノロジー・化学・医薬品企業です。1904年にJ.T.ベイカーとして創業し2010年に現社名に変更、2019年にNY証券取引所に上場し、証券コードは「AVTR」で、世界中のライフサイエンス分野の顧客に製品を提供しています。
ソムニグループ・インターナショナル・インクはアメリカ発の寝具メーカーで、マットレスをはじめとする各種ベッド用品の研究開発・設計・製造・販売を主力事業としている。米国国内外の市場に商品を供給し、利用者から高い評価を得ている。
AVTR vs SGI — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $1.7B | $1.9B |
| 純利益 | $52.4M | $140.8M |
| 粗利率 | 31.5% | 44.0% |
| 営業利益率 | 7.6% | 13.2% |
| 純利益率 | 3.1% | 7.5% |
| 売上前年比 | -1.4% | 54.7% |
| 純利益前年比 | -89.5% | 95.8% |
| EPS(希薄化後) | $0.08 | $0.71 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.7B | $1.9B | ||
| Q3 25 | $1.6B | $2.1B | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.7B | $1.2B | ||
| Q3 24 | $1.7B | $1.3B | ||
| Q2 24 | $1.7B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
| Q4 25 | $52.4M | $140.8M | ||
| Q3 25 | $-711.8M | $177.4M | ||
| Q2 25 | $64.7M | $99.0M | ||
| Q1 25 | $64.5M | $-33.1M | ||
| Q4 24 | $500.4M | $71.9M | ||
| Q3 24 | $57.8M | $130.0M | ||
| Q2 24 | $92.9M | $106.1M | ||
| Q1 24 | $60.4M | $76.3M |
| Q4 25 | 31.5% | 44.0% | ||
| Q3 25 | 32.4% | 44.9% | ||
| Q2 25 | 32.9% | 44.0% | ||
| Q1 25 | 33.8% | 36.2% | ||
| Q4 24 | 33.4% | 43.3% | ||
| Q3 24 | 32.9% | 45.4% | ||
| Q2 24 | 34.1% | 44.9% | ||
| Q1 24 | 34.0% | 43.1% |
| Q4 25 | 7.6% | 13.2% | ||
| Q3 25 | -40.0% | 14.8% | ||
| Q2 25 | 7.7% | 9.6% | ||
| Q1 25 | 9.3% | 0.8% | ||
| Q4 24 | 37.8% | 10.6% | ||
| Q3 24 | 7.3% | 15.5% | ||
| Q2 24 | 10.3% | 14.0% | ||
| Q1 24 | 8.7% | 11.1% |
| Q4 25 | 3.1% | 7.5% | ||
| Q3 25 | -43.8% | 8.4% | ||
| Q2 25 | 3.8% | 5.3% | ||
| Q1 25 | 4.1% | -2.1% | ||
| Q4 24 | 29.7% | 6.0% | ||
| Q3 24 | 3.4% | 10.0% | ||
| Q2 24 | 5.5% | 8.6% | ||
| Q1 24 | 3.6% | 6.4% |
| Q4 25 | $0.08 | $0.71 | ||
| Q3 25 | $-1.04 | $0.83 | ||
| Q2 25 | $0.09 | $0.47 | ||
| Q1 25 | $0.09 | $-0.17 | ||
| Q4 24 | $0.73 | $0.40 | ||
| Q3 24 | $0.08 | $0.73 | ||
| Q2 24 | $0.14 | $0.60 | ||
| Q1 24 | $0.09 | $0.43 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $365.4M | — |
| 総負債低いほど良い | $3.9B | $4.6B |
| 株主資本純資産 | $5.6B | $3.1B |
| 総資産 | $11.8B | $11.6B |
| 負債/資本比率低いほどレバレッジが低い | 0.71× | 1.47× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $365.4M | — | ||
| Q3 25 | $251.9M | — | ||
| Q2 25 | $449.4M | — | ||
| Q1 25 | $315.7M | — | ||
| Q4 24 | $261.9M | — | ||
| Q3 24 | $285.3M | — | ||
| Q2 24 | $272.6M | — | ||
| Q1 24 | $234.9M | — |
| Q4 25 | $3.9B | $4.6B | ||
| Q3 25 | $3.9B | $4.5B | ||
| Q2 25 | $4.2B | $4.8B | ||
| Q1 25 | $4.1B | $4.9B | ||
| Q4 24 | $4.1B | $3.7B | ||
| Q3 24 | $4.9B | $2.2B | ||
| Q2 24 | $5.1B | $2.4B | ||
| Q1 24 | $5.3B | $2.5B |
| Q4 25 | $5.6B | $3.1B | ||
| Q3 25 | $5.6B | $3.0B | ||
| Q2 25 | $6.3B | $2.8B | ||
| Q1 25 | $6.1B | $2.7B | ||
| Q4 24 | $6.0B | $559.0M | ||
| Q3 24 | $5.6B | $564.5M | ||
| Q2 24 | $5.4B | $411.8M | ||
| Q1 24 | $5.3B | $326.6M |
| Q4 25 | $11.8B | $11.6B | ||
| Q3 25 | $11.7B | $11.4B | ||
| Q2 25 | $12.8B | $11.4B | ||
| Q1 25 | $12.3B | $11.3B | ||
| Q4 24 | $12.1B | $6.0B | ||
| Q3 24 | $12.8B | $4.6B | ||
| Q2 24 | $12.7B | $4.6B | ||
| Q1 24 | $12.8B | $4.6B |
| Q4 25 | 0.71× | 1.47× | ||
| Q3 25 | 0.69× | 1.51× | ||
| Q2 25 | 0.67× | 1.69× | ||
| Q1 25 | 0.67× | 1.79× | ||
| Q4 24 | 0.68× | 6.69× | ||
| Q3 24 | 0.89× | 3.95× | ||
| Q2 24 | 0.94× | 5.92× | ||
| Q1 24 | 1.00× | 7.74× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $152.7M | $99.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $117.2M | $41.1M |
| FCFマージンFCF / 売上 | 7.0% | 2.2% |
| 設備投資強度設備投資 / 売上 | 2.1% | 3.1% |
| キャッシュ転換率営業CF / 純利益 | 2.91× | 0.71× |
| 直近12ヶ月FCF直近4四半期 | $495.0M | $633.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $152.7M | $99.4M | ||
| Q3 25 | $207.4M | $408.2M | ||
| Q2 25 | $154.4M | $186.1M | ||
| Q1 25 | $109.3M | $106.4M | ||
| Q4 24 | $173.3M | $129.1M | ||
| Q3 24 | $244.8M | $256.6M | ||
| Q2 24 | $281.1M | $150.6M | ||
| Q1 24 | $141.6M | $130.2M |
| Q4 25 | $117.2M | $41.1M | ||
| Q3 25 | $171.7M | $360.3M | ||
| Q2 25 | $124.8M | $149.4M | ||
| Q1 25 | $81.3M | $82.4M | ||
| Q4 24 | $145.8M | $108.2M | ||
| Q3 24 | $204.0M | $240.2M | ||
| Q2 24 | $235.3M | $122.1M | ||
| Q1 24 | $106.9M | $98.7M |
| Q4 25 | 7.0% | 2.2% | ||
| Q3 25 | 10.6% | 17.0% | ||
| Q2 25 | 7.4% | 7.9% | ||
| Q1 25 | 5.1% | 5.1% | ||
| Q4 24 | 8.6% | 9.0% | ||
| Q3 24 | 11.9% | 18.5% | ||
| Q2 24 | 13.8% | 9.9% | ||
| Q1 24 | 6.4% | 8.3% |
| Q4 25 | 2.1% | 3.1% | ||
| Q3 25 | 2.2% | 2.3% | ||
| Q2 25 | 1.8% | 2.0% | ||
| Q1 25 | 1.8% | 1.5% | ||
| Q4 24 | 1.6% | 1.7% | ||
| Q3 24 | 2.4% | 1.3% | ||
| Q2 24 | 2.7% | 2.3% | ||
| Q1 24 | 2.1% | 2.6% |
| Q4 25 | 2.91× | 0.71× | ||
| Q3 25 | — | 2.30× | ||
| Q2 25 | 2.39× | 1.88× | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | 1.80× | ||
| Q3 24 | 4.24× | 1.97× | ||
| Q2 24 | 3.03× | 1.42× | ||
| Q1 24 | 2.34× | 1.71× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
SGI
| Mattress Firm Segment | $892.1M | 48% |
| Tempur Sealy North America Segment | $620.5M | 33% |
| Tempur Sealy International Segment | $355.8M | 19% |